

Curriculum Vitae – Margus Viigimaa

Margus Viigimaa

MD, PhD, FESC

Cardiologist, Professor

Head of the Heart Health Centre and Research Chief of
Cardiology Centre of North Estonia Medical Centre
Professor of Cardiovascular Medicine, Tallinn University of
Technology



**National CVD Prevention
Coordinator for Estonia**

Contact: [email](#)

Short CV

Margus Viigimaa is Head of the Heart Health Centre, North Estonia Medical Centre and Professor of Cardiovascular Medicine, Tallinn University of Technology.

His main research fields are hypertension, dyslipidemia and cardiovascular prevention. He has done postdoctoral research at Kyoto University (Japan, 1990-1991). M. Viigimaa has published more than 240 original scientific papers. He is member of the editorial board of the journals Blood Pressure, Journal of System Hypertension, Romanian Journal of Cardiology, Russian Journal of Cardiology, Journal of Cardiology and Therapy.

Prof. Viigimaa is

- President of the Estonian Society of Cardiology
- Past President of the Baltic Atherosclerosis Society
- Vice president of the Estonian Society of Hypertension
- Honorary member of the
 - Swedish Society of Hypertension
 - Hungarian Society of Hypertension
 - Bulgarian Hypertension League.
- Director of Estonian WHO CINDI Programme
- Chairman of the Estonian CVD Prevention Programme
- Member of the Board of the Estonian Heart Strategy

M. Viigimaa has been an invited speaker and chairman on numerous international meetings including European Meetings on Hypertension, ESC Congresses, World Congress of Angiology, Baltic-Nordic Hypertension Meetings, Baltic Atherosclerosis Congresses, Nordic-Baltic Cardiology Congresses etc.

Addendum to Margus Viigimaa's Curriculum Vitae

Recent Publications

1. Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; **Viigimaa, M.** et al. (2013). 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *European Heart Journal*, 2159 - 2219.
2. **Viigimaa M**, Talvik A, Wojciechowska W, Kawecka-Jaszcz K, et al. (2013). Identification of the hemodynamic modulators and hemodynamic status in uncontrolled hypertensive patients. *Blood Pressure*, 362 - 370.
3. Doulas, M.; **Viigimaa, M.**; Papademetriou, V. (2013). Combined Antihypertensive Therapy and Sexual Dysfunction: Terra Incognita. *Cardiology*, 232 - 234.
4. Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Bohm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; Galderisi, M.; Grobbee, DE.; Jaarsma, T.; Kirchhof, P.; Kjeldsen, SE.; Laurent, S.; Manolis, AJ.; Nilsson, PM.; Ruilope, LM.; Schmieder, RE.; Sirnes, PA.; Sleight, P.; **Viigimaa, M.**; Waeber, B.; Zannad, F. (2013). 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). *Journal of Hypertension*, 1925 - 1938.
5. Kottgen, A.; Albrecht, E.; Teumer, A.; Vitart, V.; Krumsiek, J.; **Viigimaa M** et al. (2013). Genome-wide association analyses identify 18 new loci associated with serum urate concentrations.. *Nature Genetics*, 145 - 154.
6. Ryden, L.; Grant, PJ; Anker, SD; Berne, C.; Cosentino, F.; **Viigimaa, M.** et al. (2013). ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *European Heart Journal*, 34, 3035 - 87.
7. Pilt, K.; Ferenets, R.; Meigas, K.; Lindberg, LG; Temitski, K; **Viigimaa, M.** (2013). New Photoplethysmographic Signal Analysis Algorithm for Arterial Stiffness Estimation. *The Scientific World Journal*, 2013, 169035.
8. Johnson, T.; Gaunt, T.R.; Newhouse, S.J.; Padmanabhan, S.; Tomaszewski, M.; **Viigimaa M** et al. The Global BPgen Consortium (2011). Blood Pressure Loci Identified with a Gene-Centric Array. *American Journal of Human Genetics*, 89(6), 688 - 700.
9. Kaldmäe, M; Zilmer, M; **Viigimaa, M**; Zemtsovskaja, G; Tomberg, K; Kaart, T; Annuk, M. (2011). Cardiovascular disease risk factors in homeless people. *Uppsala Journal of Medical Sciences*, 116(3), 200 - 2007.
10. Lankin, V.; **Viigimaa, M.**; Tikhaze, A.; Kumskova, E. et al. (2011). Cholesterol-rich low density lipoproteins are also more oxidized. *Molecular and Cellular Biochemistry*, 355, 187 - 191.
11. The International Consortium for Blood Pressure Genome-Wide

Association Studies, incl. Söber, S.; Snieder, H.; Org, E.; Veldre, G.; **Viigimaa, M.**; Laan, M. (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*, 478(7367), 103 - 109.

12. **Viigimaa, M.**; Abina, J.; Zemtsovskaya, G.; Tikhaze, A.; Konovalova, G.; Kumskova, E.; Lankin, V. (2010). Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis. *Blood Pressure*, 164 - 168.
13. Vaverkova, H.; Farnier, M.; Aversa, M.; Missault, L; **Viigimaa, M.** et al. (2010). Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy. *Cardiovascular Therapeutics*, 1 - 14.
14. Varis, J.; Karjalainen, S.; Korhonen, K.; **Viigimaa, M.**; Port, K.; Kantola, I. (2009). Experiences of Telemedicine-Aided Hypertension Control in the Follow-Up of Finnish Hypertensive Patients. *Telemedicine Journal and e-Health*, 15(8), 764 - 769.